A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

Completed · Phase 1

Conditions studied: Renal Impairment

In brief

The primary purpose of this study is to assess the effect of renal impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe renal impairment relative to matched participants with normal renal function.

Key facts

Study ID

NCT05940402

Run by

AbbVie

People needed

58

Starts

2023-07-24

Expected to finish

2024-12-19

Last updated by the study team

2025-04-04

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

Where it is running

• Tustin, California — Tustin, California, United States
• Miami, Florida — Miami, Florida, United States
• Miami, Florida — Miami, Florida, United States
• Orlando, Florida — Orlando, Florida, United States
• Knoxville, Tennessee — Knoxville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.